Tourette Syndrome (Central Nervous System) - Drugs in Development, 2021

Published: March 31, 2021 |

Global Markets Direct | 74 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Product Code: GMDHC12768IDB

Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Adeptio Pharmaceuticals Ltd
Asarina Pharma AB
Emalex Biosciences Inc
Evero Health Ltd
Noema Pharma AG
Octapharma AG
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Tourette Syndrome - Drug Profiles
alpha-dihydrotetrabenazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevantolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabenazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
Feb 20, 2020: Teva's deutetrabenazine fails in paediatric Tourette syndrome trials
Aug 28, 2019: Emalex Biosciences receives FDA Fast Track Designation for Ecopipam for the treatment of patients with Tourette Syndrome
Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer